{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:21:00Z","timestamp":1789021260859,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.medin.2020.06.017","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T21:33:52Z","timestamp":1594503232000},"page":"104-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tratamiento farmacol\u00f3gico de la COVID-19: revisi\u00f3n narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)"],"prefix":"10.1016","volume":"45","author":[{"given":"E.","family":"D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Am\u00e9zaga Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vidal Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Escapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Suberviola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Serrano L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Marcos Neira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Quintana D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Catal\u00e1n Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medin.2020.06.017_bib0535","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medin.2020.06.017_bib0540","unstructured":"WHO Director-General's opening remarks at the media briefing on COVID-19-2020 [Internet] [citado 13 Abr 2020]. Disponible en: https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020"},{"key":"10.1016\/j.medin.2020.06.017_bib0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.medin.2020.03.006","article-title":"Contingency plan for the intensive care services for the COVID-19 pandemic","author":"Rascado Sedes","year":"2020","journal-title":"Med Intensiva."},{"key":"10.1016\/j.medin.2020.06.017_bib0550","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan China: A single-centered, retrospective, observational study","author":"Yang","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0555","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0560","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","author":"Grasselli","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.medin.2020.06.017_bib0565","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review","author":"Sanders","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.medin.2020.06.017_bib0570","author":"Bhimraj","year":"2020","journal-title":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19."},{"key":"10.1016\/j.medin.2020.06.017_bib0575","article-title":"From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic","author":"Estella","year":"2020","journal-title":"Med Intensiva."},{"key":"10.1016\/j.medin.2020.06.017_bib0580","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant."},{"key":"10.1016\/j.medin.2020.06.017_bib0585","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: Initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax."},{"key":"10.1016\/j.medin.2020.06.017_bib0590","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-\u03b1 for Middle East respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir Ther (Lond)."},{"key":"10.1016\/j.medin.2020.06.017_bib0595","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med [Internet]."},{"key":"10.1016\/j.medin.2020.06.017_bib0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: A retrospective cohort study","author":"Deng","year":"2020","journal-title":"J Infect."},{"key":"10.1016\/j.medin.2020.06.017_bib0605","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"10.1016\/j.medin.2020.06.017_bib0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","author":"Zhu","year":"2020","journal-title":"J Infect."},{"key":"10.1016\/j.medin.2020.06.017_bib0615","article-title":"Experimental treatment with favipiravir for COVID-19: An open-label control study","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)."},{"key":"10.1016\/j.medin.2020.06.017_bib0620","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medin.2020.06.017_bib0625","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"De Wit","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.medin.2020.06.017_bib0630","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0635","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medin.2020.06.017_bib0640","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - Preliminary report","author":"Beigel","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0645","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","author":"Goldman","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0650","unstructured":"Tratamientos disponibles sujetos a condiciones especiales de acceso para el manejo de la infecci\u00f3n respiratoria por SARS-CoV-2 [Internet]. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios [citado 7 Jun 2020]. Disponible en: https:\/\/www.aemps.gob.es\/la-aemps\/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119\/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2\/"},{"key":"10.1016\/j.medin.2020.06.017_bib0655","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.medin.2020.06.017_bib0660","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medin.2020.06.017_bib0665","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitrovitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medin.2020.06.017_bib0670","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.medin.2020.06.017_bib0675","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medin.2020.06.017_bib0680","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends."},{"key":"10.1016\/j.medin.2020.06.017_bib0685","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Chen","year":"2020","journal-title":"J Zhejiang Univ (Med Sci)."},{"key":"10.1016\/j.medin.2020.06.017_bib0690","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.medin.2020.06.017_bib0695","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medin.2020.06.017_bib0700","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","author":"Rosenberg","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.medin.2020.06.017_bib0705","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J Clin Virol."},{"key":"10.1016\/j.medin.2020.06.017_bib0710","doi-asserted-by":"crossref","first-page":"e1977","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis","volume":"28","author":"Morra","year":"2018","journal-title":"Rev Med Virol."},{"key":"10.1016\/j.medin.2020.06.017_bib0715","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis."},{"key":"10.1016\/j.medin.2020.06.017_bib0720","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medin.2020.06.017_bib0725","first-page":"294","article-title":"[Interferon beta as a therapy for m\u00faltiple sclerosis]","volume":"26","author":"Zaragoz\u00e1 Garc\u00eda","year":"2002","journal-title":"Farm Hosp."},{"key":"10.1016\/j.medin.2020.06.017_bib0730","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunologic features in severe and moderate coronavirus disease 2019","author":"Chen","year":"2020","journal-title":"J Clin Invest."},{"key":"10.1016\/j.medin.2020.06.017_bib0735","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0740","first-page":"CD010406","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"3","author":"Rodrigo","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.medin.2020.06.017_bib0745","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/CCM.0000000000004093","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza: An updated Cochrane Systematic Review and meta-analysis","volume":"48","author":"Lansbury","year":"2020","journal-title":"Crit Care Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0750","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0755","doi-asserted-by":"crossref","first-page":"416","DOI":"10.5694\/mja2.50577","article-title":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)","volume":"212","author":"Zha","year":"2020","journal-title":"Med J Aust."},{"key":"10.1016\/j.medin.2020.06.017_bib0760","article-title":"Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: Single-center experience from Wuhan, China","author":"Wang","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.medin.2020.06.017_bib0765","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-020-0127-9","article-title":"Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia","volume":"5","author":"Zhou","year":"2020","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.medin.2020.06.017_bib0770","first-page":"12","author":"Wilson","year":"2020","journal-title":"COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force"},{"key":"10.1016\/j.medin.2020.06.017_bib0775","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0780","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medin.2020.06.017_bib0785","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13063-016-1456-4","article-title":"Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: Study protocol for a randomized controlled trial","volume":"17","author":"Villar","year":"2016","journal-title":"Trials."},{"key":"10.1016\/j.medin.2020.06.017_bib0790","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.micinf.2012.10.008","article-title":"Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response","volume":"15","author":"Li","year":"2013","journal-title":"Microbes Infect."},{"issue":"Pt 12","key":"10.1016\/j.medin.2020.06.017_bib0795","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1099\/vir.0.055533-0","article-title":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment","volume":"94","author":"Lau","year":"2013","journal-title":"J Gen Virol."},{"key":"10.1016\/j.medin.2020.06.017_bib0800","article-title":"Aberrant pathogenic GM-CSF+T cells and inflammatory CD14+CD16++monocytes in severe pulmonary syndrome patients of a new coronavirus [Internet]","author":"Zhou","year":"2020","journal-title":"Immunology;"},{"issue":"10229","key":"10.1016\/j.medin.2020.06.017_bib0805","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medin.2020.06.017_bib0810","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."},{"key":"10.1016\/j.medin.2020.06.017_bib0815","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.medin.2019.01.009","article-title":"Cytokine release syndrome. Reviewing a new entity in the intensive care unit","volume":"43","author":"Garc\u00eda Roche","year":"2019","journal-title":"Med Intensiva."},{"key":"10.1016\/j.medin.2020.06.017_bib0820","doi-asserted-by":"crossref","unstructured":"Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A.\u00a02020;117(20):10970-15.\u00a0doi: 10.1073\/pnas.2005615117.","DOI":"10.1073\/pnas.2005615117"},{"key":"10.1016\/j.medin.2020.06.017_bib0825","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","author":"Luo","year":"2020","journal-title":"J Med Virol."},{"key":"10.1016\/j.medin.2020.06.017_bib0830","unstructured":"Ficha t\u00e9cnica ROACTEMRA 20mg\/ml, concentrado para soluci\u00f3n para perfusi\u00f3n [Internet]. [citado 20 Abr 2020]. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/08492001\/FT_08492001.html"},{"key":"10.1016\/j.medin.2020.06.017_bib0835","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medin.2020.06.017_bib0840","unstructured":"Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment. 7th ed. [Internet] [citado 20 Abr 2020]. Disponible en: http:\/\/kjfy.meetingchina.org\/msite\/news\/show\/cn\/3337.html"},{"key":"10.1016\/j.medin.2020.06.017_bib0845","article-title":"Potential therapeutic agents against COVID-19: What we know so far","author":"Lu","year":"2020","journal-title":"J Chin Med Assoc."},{"key":"10.1016\/j.medin.2020.06.017_bib0850","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medin.2020.06.017_bib0855","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.medin.2020.06.017_bib0860","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30262-0","article-title":"Baricitinib for COVID-19: A suitable treatment?","author":"Favalli","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.medin.2020.06.017_bib0865","unstructured":"CIMA: olumiant 4mg comprimidos recubiertos con pel\u00edcula [Internet]. [citado 20 Abr 2020]. Disponible en: https:\/\/cima.aemps.es\/cima\/publico\/detalle.html?nregistro=1161170010"},{"key":"10.1016\/j.medin.2020.06.017_bib0870","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0875","article-title":"Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome","author":"Adam Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.medin.2020.06.017_bib0880","unstructured":"Ficha t\u00e9cnica Kineret 100mg\/0,67ml solucion inyectable en jeringa precargada [Internet] [citado 11 Abr 2020]. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/102203006\/FT_102203006.html"},{"key":"10.1016\/j.medin.2020.06.017_bib0885","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040909","article-title":"Exploring the relevance of senotherapeutics for the current SARS-CoV-2 emergency and similar future global health threats","volume":"9","author":"Malavolta","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.medin.2020.06.017_bib0890","unstructured":"Ficha t\u00e9cnica Jakavi 5mg comprimidos [Internet]. [citado 23 Abr 2020]. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/112773005\/FT_112773005.html"},{"key":"10.1016\/j.medin.2020.06.017_bib0895","article-title":"Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support [Internet]","author":"Gritti","year":"2020","journal-title":"Respiratory Medicine;"},{"key":"10.1016\/j.medin.2020.06.017_bib0900","unstructured":"CIMA: Sylvant 100mg polvo para concentrado para solucion para perfusi\u00f3n [Internet]. [citado 23 Abr 2020]. Disponible en: https:\/\/cima.aemps.es\/cima\/publico\/detalle.html?nregistro=114928001"},{"key":"10.1016\/j.medin.2020.06.017_bib0905","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0910","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","author":"Wang","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.medin.2020.06.017_bib0915","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medin.2020.06.017_bib0920","doi-asserted-by":"crossref","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ."},{"key":"10.1016\/j.medin.2020.06.017_bib0925","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.medin.2020.06.017_bib0930","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.medin.2020.06.017_bib0935","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14850","article-title":"Hypercoagulability of COVID-19 patients in Intensive Care Unit. A report of Thromboelastography Findings and other Parameters of Hemostasis","author":"Panigada","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.medin.2020.06.017_bib0940","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","author":"Klok","year":"2020","journal-title":"Thromb Res."},{"key":"10.1016\/j.medin.2020.06.017_bib0945","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res."},{"key":"10.1016\/j.medin.2020.06.017_bib0950","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study","author":"Helms","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medin.2020.06.017_bib0955","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.thromres.2020.04.028","article-title":"Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom","volume":"191","author":"Thomas","year":"2020","journal-title":"Thromb Res."},{"key":"10.1016\/j.medin.2020.06.017_bib0960","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19","author":"Middeldorp","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.medin.2020.06.017_bib0965","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res."},{"key":"10.1016\/j.medin.2020.06.017_bib0970","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","author":"Tang","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.medin.2020.06.017_bib0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19","author":"Paranjpe","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medin.2020.06.017_bib0980","author":"Hunt","year":"2020","journal-title":"Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19 [Internet]."},{"key":"10.1016\/j.medin.2020.06.017_bib0985","doi-asserted-by":"crossref","unstructured":"Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. [citado 21 Abr 2020]. J Thromb Haemost [Internet]. 2020; 18:1023-1026. doi: 10.1111\/jth.14810.","DOI":"10.1111\/jth.14810"},{"key":"10.1016\/j.medin.2020.06.017_bib0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: Implications for prevention antithrombotic therapy, and follow-up","author":"Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medin.2020.06.017_bib0995","unstructured":"Kreuziger LB, Lee A, Garcia D, Cuker A, Cushman M, Connors JM. COVID-19 and VTE\/anticoagulation: Frequently asked questions [Internet]. [citado 18 Abr 2020]. Disponible en: https:\/\/www.hematology.org\/covid-19\/covid-19-and-vte-anticoagulation"},{"key":"10.1016\/j.medin.2020.06.017_bib1000","unstructured":"Lee A, deSancho M, Pai M, Huisman M, Moll S, Ageno W. COVID-19 and pulmonary embolism: Frequently asked questions [Internet]. 2020 [citado 18 Abr 2020]. Disponible en: https:\/\/www.hematology.org\/covid-19\/covid-19-and-pulmonary-embolism"},{"key":"10.1016\/j.medin.2020.06.017_bib1005","unstructured":"Recomendaciones de tromboprofilaxis y tratamiento antitromb\u00f3tico en pacientes con COVID-19 \u2013COVID-19\u2013 Sociedad Espa\u00f1ola de Trombosis y Hemostasia [Internet] [citado 7 Jun 2020]. Disponible en: https:\/\/www.covid-19.seth.es\/recomendaciones-de-tromboprofilaxis-y-tratamiento-antitrombotico-en-pacientes-con-covid-19\/"},{"key":"10.1016\/j.medin.2020.06.017_bib1010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis."},{"key":"10.1016\/j.medin.2020.06.017_bib1015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.medin.2020.06.017_bib1020","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.medin.2020.06.017_bib1025","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial","author":"Li","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.medin.2020.06.017_bib1030","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.10218","article-title":"A randomized trial of convalescent plasma for covid-19-potentially hopeful signals","author":"Casadevall","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.medin.2020.06.017_bib1035","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa102","article-title":"High- dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.medin.2020.06.017_bib1040","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France","author":"Million","year":"2020","journal-title":"Travel Med Infect Dis."},{"key":"10.1016\/j.medin.2020.06.017_bib1045","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.medin.2020.06.017_bib1050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","author":"Geleris","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medin.2020.06.017_bib1055","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14830","article-title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia","author":"Cui","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.medin.2020.06.017_bib1060","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14869","article-title":"High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients","author":"Llitjos","year":"2020","journal-title":"J Thromb Haemost."}],"container-title":["Medicina Intensiva"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210569120302473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210569120302473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:40:08Z","timestamp":1759322408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210569120302473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0210569120302473"],"URL":"https:\/\/doi.org\/10.1016\/j.medin.2020.06.017","relation":{},"ISSN":["0210-5691"],"issn-type":[{"value":"0210-5691","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento farmacol\u00f3gico de la COVID-19: revisi\u00f3n narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2020.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a,  S.L.U. y SEMICYUC. All rights reserved.","name":"copyright","label":"Copyright"}]}}